Is a cure for Parkinson's disease hiding inside us?

alpha-Synuclein (a-syn) oligomers and fibrils are behind neurodegeneration in Parkinson's disease (PD), but therapeutically targeting them is challenging. Amphipathic and cationic helical peptides inhibit amyloid formation and suppress neurotoxicity by selectively binding the solvent-accessible regions in these toxic species. Can endogenous peptides, like LL-37, constitute a new therapeutic paradigm in PD?

Automated summary

alpha-Synuclein oligomers and fibrils play a role in neurodegeneration in Parkinson's disease. Amphipathic and cationic helical peptides can inhibit amyloid formation and neurotoxicity by binding to solvent-accessible regions in these toxic species. Can endogenous peptides like LL-37 be a new therapeutic approach in PD?